EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Wednesday, May 7th. Analysts expect EyePoint Pharmaceuticals to post earnings of ($0.65) per share and revenue of $8.84 million for the quarter.
EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The company had revenue of $11.60 million during the quarter, compared to the consensus estimate of $11.02 million. On average, analysts expect EyePoint Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
EyePoint Pharmaceuticals Stock Performance
NASDAQ EYPT traded down $0.44 during trading hours on Monday, hitting $6.86. 460,264 shares of the company traded hands, compared to its average volume of 877,881. The business's 50-day moving average is $6.02 and its 200-day moving average is $7.60. The stock has a market capitalization of $472.04 million, a price-to-earnings ratio of -3.43 and a beta of 1.39. EyePoint Pharmaceuticals has a twelve month low of $3.91 and a twelve month high of $14.00.
Wall Street Analyst Weigh In
Several research firms recently weighed in on EYPT. Citigroup initiated coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating and a $33.00 target price for the company. Chardan Capital reissued a "buy" rating and issued a $33.00 price objective on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a "sell" rating in a research note on Friday, March 14th. Finally, HC Wainwright reiterated a "buy" rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. One analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. Based on data from MarketBeat, EyePoint Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $26.63.
View Our Latest Stock Report on EYPT
EyePoint Pharmaceuticals Company Profile
(
Get Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
See Also
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
